MCID: HYP025
MIFTS: 49

Hyperphosphatemia

Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

MalaCards integrated aliases for Hyperphosphatemia:

Name: Hyperphosphatemia 12 29 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 44 D054559
NCIt 50 C113750
SNOMED-CT 68 20165001
UMLS 73 C0085681

Summaries for Hyperphosphatemia

Disease Ontology : 12 A phosphorus metabolism disease characterized by hyperphosphatemia and abnormal deposits of phosphate and calcium in joints and soft tissues, results from abnomral phosphorus metabolism and has material basis in mutations in the FGF23, GALNT3 or KL gene.

MalaCards based summary : Hyperphosphatemia is related to tumoral calcinosis, hyperphosphatemic, familial, 1 and pseudohypoparathyroidism, type ib. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Endochondral Ossification. The drugs Calcium Carbonate and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and colon, and related phenotypes are growth/size/body region and cardiovascular system

Wikipedia : 76 Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial, 1 33.5 FGF23 GALNT3 KL
2 pseudohypoparathyroidism, type ib 32.0 GNAS PTH STX16
3 hypoparathyroidism, familial isolated 31.6 CASR GCM2 PTH
4 hypocalcemia, autosomal dominant 1 31.0 CASR FGF23 GCM2 GNAS PTH VDR
5 hyperostosis 30.8 FGF23 GALNT3 KL
6 chronic kidney failure 30.5 CASR FGF23 PTH VDR
7 calcinosis 30.3 FGF23 GALNT3 KL MGP PHEX
8 familial tumoral calcinosis 30.3 FGF23 GALNT3 KL PHEX
9 kidney disease 30.3 CASR FGF23 MGP PTH VDR
10 hypophosphatemia 30.1 FGF23 PHEX PTH SLC34A1
11 uremia 30.0 CASR PTH VDR
12 secondary hyperparathyroidism of renal origin 29.9 CASR FGF23 PTH VDR
13 hyperparathyroidism 29.8 CASR FGF23 GCM2 PHEX PTH VDR
14 hypoparathyroidism 29.8 CASR FGF23 GCM2 PTH
15 hypophosphatasia 29.7 PHEX RUNX2
16 calciphylaxis 29.6 CASR FGF23 PTH VDR
17 rickets 29.3 FGF23 PHEX PTH SLC34A1 VDR
18 bone disease 29.2 CASR FGF23 PTH RUNX2 VDR
19 osteoporosis 28.3 CASR FGF23 KL MGP PTH RUNX2
20 hyperphosphatemia, polyuria, and seizures 12.2
21 tumoral calcinosis, hyperphosphatemic, familial, 2 11.2
22 tumoral calcinosis, hyperphosphatemic, familial, 3 11.2
23 pseudohypoparathyroidism, type ia 11.0
24 pseudohypoparathyroidism, type ii 11.0
25 hypoparathyroidism-retardation-dysmorphism syndrome 11.0
26 pseudohypoparathyroidism, type ic 11.0
27 leukemia 10.4
28 lymphocytic leukemia 10.3
29 tracheal calcification 10.2 FGF23 KL
30 myeloma, multiple 10.2
31 leukemia, acute lymphoblastic 10.2
32 impaired renal function disease 10.2 FGF23 PTH
33 hypothyroidism, congenital, nongoitrous, 1 10.2 GNAS STX16
34 chief cell adenoma 10.2 GCM2 PTH
35 connective tissue benign neoplasm 10.2 GNAS PTH
36 opsismodysplasia 10.2 FGF23 PHEX
37 lactic acidosis 10.2
38 enthesopathy 10.2 FGF23 PHEX
39 albright's hereditary osteodystrophy 10.1 GNAS STX16
40 pseudopseudohypoparathyroidism 10.1 GNAS PTH STX16
41 pseudohypoparathyroidism 10.1 GNAS PTH STX16
42 urinary system disease 10.1 FGF23 KL PTH
43 autosomal recessive hypophosphatemic rickets 10.1 FGF23 GALNT3 PHEX
44 hypophosphatemic rickets, autosomal dominant 10.1 FGF23 GALNT3 PHEX
45 oncogenic osteomalacia 10.1 FGF23 PHEX PTH
46 metaphyseal chondrodysplasia, jansen type 10.1 FGF23 PTH
47 vitamin d-dependent rickets, type 2a 10.1 PHEX VDR
48 pulmonary alveolar microlithiasis 10.1 FGF23 PTH SLC34A1
49 metabolic acidosis 10.1
50 osseous heteroplasia, progressive 10.0 GNAS RUNX2

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.26 CASR FGF23 GALNT3 GNAS KL MGP
2 cardiovascular system MP:0005385 10.25 FGF23 GALNT3 GNAS KL MGP PHEX
3 homeostasis/metabolism MP:0005376 10.25 CASR FGF23 GALNT3 GCM2 GNAS KL
4 cellular MP:0005384 10.19 CASR GALNT3 GCM2 GNAS KL PHEX
5 endocrine/exocrine gland MP:0005379 10.19 CASR FGF23 GALNT3 GCM2 GNAS KL
6 craniofacial MP:0005382 10.13 GALNT3 GCM2 GNAS KL PHEX PTH
7 hematopoietic system MP:0005397 10.11 CASR FGF23 GALNT3 GNAS KL PHEX
8 immune system MP:0005387 10.06 CASR FGF23 GALNT3 GNAS KL PHEX
9 digestive/alimentary MP:0005381 10.05 CASR FGF23 GALNT3 KL PHEX RUNX2
10 mortality/aging MP:0010768 10 CASR FGF23 GCM2 GNAS KL MGP
11 limbs/digits/tail MP:0005371 9.92 FGF23 GALNT3 GNAS KL PHEX PTH
12 integument MP:0010771 9.91 CASR FGF23 GALNT3 GNAS KL RUNX2
13 muscle MP:0005369 9.76 CASR GALNT3 GNAS KL MGP RUNX2
14 renal/urinary system MP:0005367 9.65 CASR FGF23 GALNT3 GCM2 GNAS KL
15 skeleton MP:0005390 9.44 CASR FGF23 GALNT3 GCM2 GNAS KL

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
2
Nicotinamide Approved, Investigational Phase 4,Phase 2,Phase 1 98-92-0 936
3
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
4
Calcium acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-54-4
5
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52757-95-6
6
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
7
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
8
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
10
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
11
Alfacalcidol Approved, Nutraceutical Phase 4,Not Applicable 41294-56-8 5282181
12
Calcitriol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 32222-06-3 5280453 134070
13
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 50-14-6 5280793
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
15
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
16
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
21 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Vitamin B9 Phase 4,Phase 2,Phase 1
24 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Lipid Regulating Agents Phase 4,Phase 2,Phase 1
26 Vitamin B3 Phase 4,Phase 2,Phase 1
27 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Antimetabolites Phase 4,Phase 2,Phase 1
29 Nicotinic Acids Phase 4,Phase 2,Phase 1
30 Hypolipidemic Agents Phase 4,Phase 2,Phase 1
31 Folate Phase 4,Phase 2,Phase 1
32 Vasodilator Agents Phase 4,Phase 2,Phase 1
33 Vitamin B Complex Phase 4,Phase 2,Phase 1
34 Ferric Compounds Phase 4,Phase 3,Phase 2
35 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
36 Citrate Phase 4,Phase 3,Phase 2,Phase 1
37 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hematinics Phase 4,Phase 3,Phase 2
39 Hydroxycholecalciferols Phase 4,Not Applicable
40 Hormones Phase 4,Phase 3
41 Vasoconstrictor Agents Phase 4,Phase 2,Not Applicable
42 Ergocalciferols Phase 4,Phase 2,Not Applicable
43 Calciferol Phase 4,Phase 3,Phase 2,Not Applicable
44 Vitamin D2 Phase 4,Phase 2,Not Applicable
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Black Cherry Phase 4
47 Hormone Antagonists Phase 4,Phase 3
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
49 Cinacalcet Hydrochloride Phase 4
50 Calcimimetic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 179)
# Name Status NCT ID Phase Drugs
1 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
2 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
3 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
4 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
5 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4 Sevelamer HCl;Calcium-based phosphate binder
6 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
7 Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease Completed NCT00160121 Phase 4 Lanthanum carbonate
8 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
9 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
10 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
11 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Completed NCT01427907 Phase 4 Calcium acetate oral solution (COS);Sevelamer carbonate
12 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
13 Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00091481 Phase 4 Zemplar
14 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
15 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
16 TOnicity of Perioperative Maintenance SoluTions Completed NCT03080831 Phase 4 NaCl 0.9% in Glucose 5% + 40mmol/L Potassium;Glucion 5%
17 Phophate Lowering Trial Recruiting NCT02209636 Phase 4 Lanthanum carbonate;placebo;Ascorbic Acid;Nitroglycerin
18 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Active, not recruiting NCT03079869 Phase 4 Ferric Citrate
19 Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Active, not recruiting NCT03256838 Phase 4 Ferric Citrate
20 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4 Lanthanum carbonate;Calcium Carbonate
21 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
22 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
23 Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 Terminated NCT00452478 Phase 4 Lanthanum carbonate
24 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
25 Vitamin D and Carboxy PTH Fragments in Coronary Calcification Withdrawn NCT00502268 Phase 4 Doxercalciferol administration;Doxercalciferol administered by 1-84-7-84
26 Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Unknown status NCT01357317 Phase 3 Phosphorus binder
27 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3 PA21
28 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3 Tenapanor;Placebo
29 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3 Lanthanum Carbonate (BAY77-1931)
30 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3 Lanthanum carbonate (BAY77-1931);Calcium carbonate
31 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3 PA21;Sevelamer hydrochloride
32 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3 MCI-196
33 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3 PA21
34 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3 PA21
35 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3 ASP1585
36 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3 ASP1585
37 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3 ASP1585;placebo
38 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3 MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®);Placebo;Another phosphate binder (Sevelamer)
39 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3 MCI-196;Another Phosphate binder (Sevelamer)
40 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3 ASP1585
41 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3 ASP1585;Sevelamer hydrochloride
42 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3 MCI-196;Placebo
43 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931)
44 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3 MCI-196;Placebo
45 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3 Fosrenol (Lanthanum Carbonate, BAY77-1931);Placebo
46 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Completed NCT01324128 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate;PA21-1 (1.25 g tablet containing 250 mg iron)
47 A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Completed NCT01464190 Phase 3 PA21 (2.5 g tablet containing 500 mg iron);Sevelamer carbonate
48 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3 SBR759A;SBR759A;SBR759A;SBR759A;SBR759A
49 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3 ferric citrate
50 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3 Osvaren Granules;Osvaren film-coated tablets

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

# Genetic test Affiliating Genes
1 Hyperphosphatemia 29

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

41
Kidney, Bone, Colon, Liver, Heart, Smooth Muscle, Myeloid

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 499)
# Title Authors Year
1
Calcitriol accelerates vascular calcification irrespective of vitamin K status in a rat model of CKD with hyperphosphatemia and secondary hyperparathyroidism. ( 29903718 )
2018
2
Dietary Management ofA Hyperphosphatemia. ( 29655498 )
2018
3
Patient education for hyperphosphatemia management: Improving outcomes while decreasing costs? ( 29629272 )
2018
4
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. ( 29340316 )
2018
5
Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis. ( 29295646 )
2018
6
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. ( 29566839 )
2018
7
Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease. ( 29486729 )
2018
8
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. ( 29617976 )
2018
9
Current and potential treatment options for hyperphosphatemia. ( 29783873 )
2018
10
Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients. ( 29561409 )
2018
11
Prevention and treatment of hyperphosphatemia in chronic kidney disease. ( 29580635 )
2018
12
A Decision Support Tool for Healthcare Professionals in the Management of Hyperphosphatemia in Hemodialysis. ( 29678073 )
2018
13
Blood pressure and heart rate variability are linked with hyperphosphatemia in chronic kidney disease patients. ( 29947550 )
2018
14
Hyperphosphatemia is associated with high mortality in severe burns. ( 29315336 )
2018
15
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. ( 29985725 )
2018
16
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease. ( 30022383 )
2018
17
Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks. ( 30087012 )
2018
18
Hyperphosphatemia Promotes Senescence of Myoblasts by Impairing Autophagy Through Ilk Overexpression, A Possible Mechanism Involved in Sarcopenia. ( 30271655 )
2018
19
Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Questions. ( 30291427 )
2018
20
Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Answers. ( 30291428 )
2018
21
Treatment of hyperphosphatemia based on specific interactions between phosphorus and Zr(iv) active centers of nano-MOFs. ( 30319748 )
2018
22
Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders. ( 30327732 )
2018
23
Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin-1 production. ( 28857396 )
2017
24
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. ( 28550969 )
2017
25
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( 28777915 )
2017
26
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. ( 28078600 )
2017
27
Effect of Vitamin D Supplementation on Delayed Hyperphosphatemia in Pediatric Acute Lymphoblastic Leukemia Patients During Induction Chemotherapy. ( 28469534 )
2017
28
A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway. ( 29270533 )
2017
29
Cost-effectiveness of dedicated dietitians for hyperphosphatemia management among hemodialysis patients in Lebanon: results from the Nutrition Education for Management of Osteodystrophy trial. ( 28657451 )
2017
30
Analysis of Hypo- and Hyperphosphatemia in an Intensive Care Unit Cohort. ( 28525508 )
2017
31
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. ( 28321403 )
2017
32
Educational nursing intervention to reduce the hyperphosphatemia in patients on hemodialysis. ( 28226039 )
2017
33
Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients. ( 28218647 )
2017
34
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
35
Hyperphosphatemia in a patient with spinal cord injury who received etidronate for the treatment of heterotopic ossification. ( 28616259 )
2017
36
A Dialysis Patient With Hyperphosphatemia, Hyperkalemia, and Azotemia Without an Excessive Intake. ( 29142992 )
2017
37
Surface-Engineered Blood Adsorption Device for Hyperphosphatemia Treatment. ( 28799951 )
2017
38
Activation of the Nrf2-ARE Signaling Pathway Prevents Hyperphosphatemia-Induced Vascular Calcification by Inducing Autophagy in Renal Vascular Smooth Muscle Cells. ( 28513870 )
2017
39
Antibody-mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice. ( 28292888 )
2017
40
Tumor lysis syndrome with massive hyperphosphatemia and hyperuricemia. ( 29225880 )
2017
41
Uremic Tumoral Calcinosis Resolved by Improvements in Hyperphosphatemia. ( 28626193 )
2017
42
Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia. ( 28182142 )
2017
43
Hyperphosphatemia, a Cause of High Anion Gap Metabolic Acidosis: Report of a Case and Review of the Literature. ( 28450695 )
2017
44
Admission hyperphosphatemia increases the risk of acute kidney injury in hospitalized patients. ( 28975589 )
2017
45
Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode". ( 28528515 )
2017
46
Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. ( 27832343 )
2017
47
Short-Term PTH(1-34) Therapy in Children to Correct Severe Hypocalcemia and Hyperphosphatemia due to Hypoparathyroidism: Two Case Studies. ( 27957353 )
2016
48
Treating hyperphosphatemia - current and advancing drugs. ( 27643443 )
2016
49
Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. ( 27121505 )
2016
50
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. ( 27751671 )
2016

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.26 CASR GNAS KL SLC34A1
2 perinuclear region of cytoplasm GO:0048471 9.02 GALNT3 GNAS PHEX SLC34A1 STX16

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.73 CASR GCM2 PTH VDR
2 ossification GO:0001503 9.71 CASR MGP RUNX2 SLC34A1
3 fibroblast growth factor receptor signaling pathway GO:0008543 9.7 FGF23 GALNT3 KL
4 bone mineralization GO:0030282 9.62 PHEX PTH
5 embryonic cranial skeleton morphogenesis GO:0048701 9.62 GNAS RUNX2
6 positive regulation of bone mineralization GO:0030501 9.61 KL PTH
7 response to cadmium ion GO:0046686 9.61 PTH SLC34A1
8 endochondral ossification GO:0001958 9.6 GNAS RUNX2
9 regulation of bone mineralization GO:0030500 9.59 FGF23 MGP
10 response to lead ion GO:0010288 9.58 PTH SLC34A1
11 response to vitamin D GO:0033280 9.58 PHEX PTH
12 energy reserve metabolic process GO:0006112 9.57 GNAS KL
13 response to growth hormone GO:0060416 9.56 PHEX SLC34A1
14 response to magnesium ion GO:0032026 9.55 FGF23 SLC34A1
15 skeletal system development GO:0001501 9.55 GNAS PHEX PTH RUNX2 VDR
16 vitamin D metabolic process GO:0042359 9.54 FGF23 VDR
17 cellular response to vitamin D GO:0071305 9.54 CASR FGF23 PHEX
18 response to fibroblast growth factor GO:0071774 9.51 CASR PTH
19 cellular response to parathyroid hormone stimulus GO:0071374 9.5 FGF23 PHEX SLC34A1
20 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.49 FGF23 KL
21 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.48 FGF23 VDR
22 response to sodium phosphate GO:1904383 9.46 FGF23 PHEX
23 cellular phosphate ion homeostasis GO:0030643 9.43 FGF23 GCM2 SLC34A1
24 phosphate ion homeostasis GO:0055062 9.13 FGF23 PTH SLC34A1
25 response to parathyroid hormone GO:0071107 8.8 GNAS PTH SLC34A1

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.96 FGF23 KL
2 vitamin D binding GO:0005499 8.62 KL VDR

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....